Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Horwich, A, Babjuk, M, Bellmunt, J, Bruins, HM, Reijke, TMD, Santis, MD, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, MJ, Shariat, SF, Kwast, TVD, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, PC, Bochner, BH, Bolla, M, Boormans, JL, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Compérat, E, Crabb, S, Culine, S, Bari, BD, Blok, WD, De Visschere, PJL, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, JL, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, JJ, Gakis, G, Geavlete, B, Gontero, P, Grubmüller, B, Hafeez, S, Hansel, DE, Hartmann, A, Hayne, D, Henry, AM, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, BA, Jones, R, Kamat, AM, Khoo, V, Kiltie, AE, Krege, S, Ladoire, S, Lara, PC, Leliveld, A, Linares-Espinós, E, Løgager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, MC, Moschini, M, Mostafid, H, Müller, A-C, Müller, CR, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, JR, Oldenburg, J, Osanto, S, Oyen, WJG, Pacheco-Figueiredo, L, Pappot, H, Patel, MI, Pieters, BR, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, JE, Rouprêt, M, Rouvière, O, Salembier, C, Salminen, A, Sargos, P, Sengupta, S, Sherif, A, Smeenk, RJ, Smits, A, Stenzl, A, Thalmann, GN, Tombal, B, Turkbey, B, Lauridsen, SV, Valdagni, R, Van Der Heijden, AG, Van Poppel, H, Vartolomei, MD, Veskimäe, E, Vilaseca, A, Rivera, FAV, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R & Witjes, JA 2019, 'EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†' Annals of Oncology, vol. 30, no. 11, pp. 1697-1727. https://doi.org/10.1093/annonc/mdz296

APA

CBE

Horwich A, Babjuk M, Bellmunt J, Bruins HM, Reijke TMD, Santis MD, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Kwast TVD, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, Bari BD, Blok WD, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller A-C, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Witjes JA. 2019. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. Annals of Oncology. 30(11):1697-1727. https://doi.org/10.1093/annonc/mdz296

MLA

Vancouver

Author

Horwich, A ; Babjuk, M ; Bellmunt, J ; Bruins, H M ; Reijke, T M De ; Santis, M De ; Gillessen, S ; James, N ; Maclennan, S ; Palou, J ; Powles, T ; Ribal, M J ; Shariat, S F ; Kwast, T Van Der ; Xylinas, E ; Agarwal, N ; Arends, T ; Bamias, A ; Birtle, A ; Black, P C ; Bochner, B H ; Bolla, M ; Boormans, J L ; Bossi, A ; Briganti, A ; Brummelhuis, I ; Burger, M ; Castellano, D ; Cathomas, R ; Chiti, A ; Choudhury, A ; Compérat, E ; Crabb, S ; Culine, S ; Bari, B De ; Blok, W De ; De Visschere, P J L ; Decaestecker, K ; Dimitropoulos, K ; Dominguez-Escrig, J L ; Fanti, S ; Fonteyne, V ; Frydenberg, M ; Futterer, J J ; Gakis, G ; Geavlete, B ; Gontero, P ; Grubmüller, B ; Hafeez, S ; Hansel, D E ; Hartmann, A ; Hayne, D ; Henry, A M ; Hernandez, V ; Herr, H ; Herrmann, K ; Hoskin, P ; Huguet, J ; Jereczek-Fossa, B A ; Jones, R ; Kamat, A M ; Khoo, V ; Kiltie, A E ; Krege, S ; Ladoire, S ; Lara, P C ; Leliveld, A ; Linares-Espinós, E ; Løgager, V ; Lorch, A ; Loriot, Y ; Meijer, R ; Mir, M Carmen ; Moschini, M ; Mostafid, H ; Müller, A-C ; Müller, C R ; N'Dow, J ; Necchi, A ; Neuzillet, Y ; Oddens, J R ; Oldenburg, J ; Osanto, S ; Oyen, W J G ; Pacheco-Figueiredo, L ; Pappot, H ; Patel, M I ; Pieters, B R ; Plass, K ; Remzi, M ; Retz, M ; Richenberg, J ; Rink, M ; Roghmann, F ; Rosenberg, J E ; Rouprêt, M ; Rouvière, O ; Salembier, C ; Salminen, A ; Sargos, P ; Sengupta, S ; Sherif, A ; Smeenk, R J ; Smits, A ; Stenzl, A ; Thalmann, G N ; Tombal, B ; Turkbey, B ; Lauridsen, S Vahr ; Valdagni, R ; Van Der Heijden, A G ; Van Poppel, H ; Vartolomei, M D ; Veskimäe, E ; Vilaseca, A ; Rivera, F A Vives ; Wiegel, T ; Wiklund, P ; Williams, A ; Zigeuner, R ; Witjes, J A. / EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort : under the auspices of the EAU and ESMO Guidelines Committees†. In: Annals of Oncology. 2019 ; Vol. 30, No. 11. pp. 1697-1727.

Bibtex

@article{4ee73d896b144d4baf0637c3e3a623f9,
title = "EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†",
abstract = "BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference.SETTING: Online Delphi survey and consensus conference.PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70{\%} agreement and ≤15{\%} disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus).RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28{\%}) statements achieved level 1 consensus and 49 (42{\%}) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81{\%}) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease.CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach.",
author = "A Horwich and M Babjuk and J Bellmunt and Bruins, {H M} and Reijke, {T M De} and Santis, {M De} and S Gillessen and N James and S Maclennan and J Palou and T Powles and Ribal, {M J} and Shariat, {S F} and Kwast, {T Van Der} and E Xylinas and N Agarwal and T Arends and A Bamias and A Birtle and Black, {P C} and Bochner, {B H} and M Bolla and Boormans, {J L} and A Bossi and A Briganti and I Brummelhuis and M Burger and D Castellano and R Cathomas and A Chiti and A Choudhury and E Comp{\'e}rat and S Crabb and S Culine and Bari, {B De} and Blok, {W De} and {De Visschere}, {P J L} and K Decaestecker and K Dimitropoulos and Dominguez-Escrig, {J L} and S Fanti and V Fonteyne and M Frydenberg and Futterer, {J J} and G Gakis and B Geavlete and P Gontero and B Grubm{\"u}ller and S Hafeez and Hansel, {D E} and A Hartmann and D Hayne and Henry, {A M} and V Hernandez and H Herr and K Herrmann and P Hoskin and J Huguet and Jereczek-Fossa, {B A} and R Jones and Kamat, {A M} and V Khoo and Kiltie, {A E} and S Krege and S Ladoire and Lara, {P C} and A Leliveld and E Linares-Espin{\'o}s and V L{\o}gager and A Lorch and Y Loriot and R Meijer and Mir, {M Carmen} and M Moschini and H Mostafid and A-C M{\"u}ller and M{\"u}ller, {C R} and J N'Dow and A Necchi and Y Neuzillet and Oddens, {J R} and J Oldenburg and S Osanto and Oyen, {W J G} and L Pacheco-Figueiredo and H Pappot and Patel, {M I} and Pieters, {B R} and K Plass and M Remzi and M Retz and J Richenberg and M Rink and F Roghmann and Rosenberg, {J E} and M Roupr{\^e}t and O Rouvi{\`e}re and C Salembier and A Salminen and P Sargos and S Sengupta and A Sherif and Smeenk, {R J} and A Smits and A Stenzl and Thalmann, {G N} and B Tombal and B Turkbey and Lauridsen, {S Vahr} and R Valdagni and {Van Der Heijden}, {A G} and {Van Poppel}, H and Vartolomei, {M D} and E Veskim{\"a}e and A Vilaseca and Rivera, {F A Vives} and T Wiegel and P Wiklund and A Williams and R Zigeuner and Witjes, {J A}",
note = "{\circledC} The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.",
year = "2019",
month = "11",
day = "1",
doi = "10.1093/annonc/mdz296",
language = "English",
volume = "30",
pages = "1697--1727",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "11",

}

RIS

TY - JOUR

T1 - EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort

T2 - under the auspices of the EAU and ESMO Guidelines Committees†

AU - Horwich, A

AU - Babjuk, M

AU - Bellmunt, J

AU - Bruins, H M

AU - Reijke, T M De

AU - Santis, M De

AU - Gillessen, S

AU - James, N

AU - Maclennan, S

AU - Palou, J

AU - Powles, T

AU - Ribal, M J

AU - Shariat, S F

AU - Kwast, T Van Der

AU - Xylinas, E

AU - Agarwal, N

AU - Arends, T

AU - Bamias, A

AU - Birtle, A

AU - Black, P C

AU - Bochner, B H

AU - Bolla, M

AU - Boormans, J L

AU - Bossi, A

AU - Briganti, A

AU - Brummelhuis, I

AU - Burger, M

AU - Castellano, D

AU - Cathomas, R

AU - Chiti, A

AU - Choudhury, A

AU - Compérat, E

AU - Crabb, S

AU - Culine, S

AU - Bari, B De

AU - Blok, W De

AU - De Visschere, P J L

AU - Decaestecker, K

AU - Dimitropoulos, K

AU - Dominguez-Escrig, J L

AU - Fanti, S

AU - Fonteyne, V

AU - Frydenberg, M

AU - Futterer, J J

AU - Gakis, G

AU - Geavlete, B

AU - Gontero, P

AU - Grubmüller, B

AU - Hafeez, S

AU - Hansel, D E

AU - Hartmann, A

AU - Hayne, D

AU - Henry, A M

AU - Hernandez, V

AU - Herr, H

AU - Herrmann, K

AU - Hoskin, P

AU - Huguet, J

AU - Jereczek-Fossa, B A

AU - Jones, R

AU - Kamat, A M

AU - Khoo, V

AU - Kiltie, A E

AU - Krege, S

AU - Ladoire, S

AU - Lara, P C

AU - Leliveld, A

AU - Linares-Espinós, E

AU - Løgager, V

AU - Lorch, A

AU - Loriot, Y

AU - Meijer, R

AU - Mir, M Carmen

AU - Moschini, M

AU - Mostafid, H

AU - Müller, A-C

AU - Müller, C R

AU - N'Dow, J

AU - Necchi, A

AU - Neuzillet, Y

AU - Oddens, J R

AU - Oldenburg, J

AU - Osanto, S

AU - Oyen, W J G

AU - Pacheco-Figueiredo, L

AU - Pappot, H

AU - Patel, M I

AU - Pieters, B R

AU - Plass, K

AU - Remzi, M

AU - Retz, M

AU - Richenberg, J

AU - Rink, M

AU - Roghmann, F

AU - Rosenberg, J E

AU - Rouprêt, M

AU - Rouvière, O

AU - Salembier, C

AU - Salminen, A

AU - Sargos, P

AU - Sengupta, S

AU - Sherif, A

AU - Smeenk, R J

AU - Smits, A

AU - Stenzl, A

AU - Thalmann, G N

AU - Tombal, B

AU - Turkbey, B

AU - Lauridsen, S Vahr

AU - Valdagni, R

AU - Van Der Heijden, A G

AU - Van Poppel, H

AU - Vartolomei, M D

AU - Veskimäe, E

AU - Vilaseca, A

AU - Rivera, F A Vives

AU - Wiegel, T

AU - Wiklund, P

AU - Williams, A

AU - Zigeuner, R

AU - Witjes, J A

N1 - © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference.SETTING: Online Delphi survey and consensus conference.PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus).RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease.CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach.

AB - BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference.SETTING: Online Delphi survey and consensus conference.PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus).RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease.CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach.

U2 - 10.1093/annonc/mdz296

DO - 10.1093/annonc/mdz296

M3 - Journal article

VL - 30

SP - 1697

EP - 1727

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -

ID: 58931520